The significant EPS miss and declining profitability signal weakening standalone performance, but the pending Boston Scientific acquisition provides a floor. Traders should watch for any regulatory updates on the merger and consider the stock is more tied to deal completion than fundamentals near-term.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $324.65entry
- T+1 · 6mo ago −0.75%α −1.58% · $322.23
- T+5 · 6mo ago −0.63%α −2.14% · $322.59
- T+20 · 6mo ago −1.63%α −4.76% · $319.37
- T+60 · 4mo ago −0.50%α −4.34% · $323.02
Price Chart
How similar events traded
Executive Summary
Penumbra Q1 2026 earnings miss: diluted EPS of $0.82 missed consensus of $1.11 by 26%, and net income declined 17% YoY to $32.6M, despite revenue growing 15.6% to $374.8M. The company withdrew guidance due to the pending Boston Scientific acquisition, but the standalone operational weakness is notable.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $374.8M, up 15.6% YoY
- Diluted EPS $0.82 vs consensus $1.11 (miss of 26%)
- Net income $32.6M, down 17% YoY from $39.2M
- Operating income $38.2M vs $40.4M in prior year
- Gross margin improved to 67.6% from 66.6% in Q1 2025
- No FY2026 guidance provided due to pending BSX acquisition
- Acquisition-related expenses of $9.4M included in SG&A
Financial Impact
EPS miss of $0.29 (26%) against consensus; operating and net income declined YoY despite revenue growth.
Risk Factors
- Acquisition failure or delay could expose stock to full operational downside
- Further earnings deterioration if acquisition closes later than expected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001321732-26-000018 |
| Document: pen-20260506.htm | 0001321732-26-000018 |
| Document: 0001321732-26-000018-index-headers.html | 0001321732-26-000018 |
| Document: 0001321732-26-000018-index.html | 0001321732-26-000018 |
| Document: 0001321732-26-000018.txt | 0001321732-26-000018 |
| 8-K Data (Synthetic) | 0001321732-26-000018 |
Track record
11 reports on PEN
0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: −0.15% at T+1 after the Apr 1, 2026 report. 0 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
- May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Viewing Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
- Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers